SillaJen, Inc. (KOSDAQ: 215600)
South Korea
· Delayed Price · Currency is KRW
2,510.00
+60.00 (2.45%)
Dec 30, 2024, 9:00 AM KST
SillaJen Company Description
SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea.
Its lead product is Pexa-Vec for the treatment of advanced liver cancer. The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine.
SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
SillaJen, Inc.
Country | South Korea |
Founded | 2006 |
Industry | Biological Products, Except Diagnostic Substances |
Employees | 37 |
CEO | Jaekyung Kim |
Contact Details
Address: 109, Sogong-ro Seoul, 04525 South Korea | |
Phone | 82 2 368 2600 |
Website | sillajen.com |
Stock Details
Ticker Symbol | 215600 |
Exchange | KOSDAQ |
Fiscal Year | January - December |
Reporting Currency | KRW |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Jaekyung Kim | Chief Executive Officer |
Suk Song Myung | Chief Financial Officer |